To evaluate the significance of clinical abnormalities occurring during the peri-engraftment period following allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed the data of 216 allogeneic HCT recipients. The most frequently observed peri-engraftment clinical abnormality (PECA) was noninfectious fever in 58 patients, followed by hepatic dysfunction in 39, weight gain in 22, and renal insufficiency in 11. Frequently identified predictive factors for a higher incidence of each PECA were HCT from an unrelated or mismatched donor, GVHD prophylaxis with cyclosporine alone, and rapid engraftment. Considering that donor type and GVHD prophylaxis are closely related to GVHD, these observations suggest that the development of PECAs might be associated with a graft-versus-host reaction. This hypothesis was supported by the fact that the patient group with each PECA showed a higher incidence of grades 3-4 acute or chronic extensive GVHD, with varying degrees of statistical significance. Although our data should be interpreted cautiously in view of their retrospective nature, some of the PECAs occurring after allogeneic HCT may be atypical manifestations of GVHD and may be associated with severe forms of acute or chronic GVHD. Bone Marrow Transplantation (2003) 32, 809-813. doi:10.1038/sj.bmt.1704224 Keywords: peri-engraftment clinical abnormality; allogeneic hematopoietic cell transplantation; graft-versus-host disease; engraftment syndrome Following hematopoietic cell transplantation (HCT), various clinical abnormalities such as noninfectious fever, weight gain due to capillary leakage, hepatic dysfunction, and renal insufficiency have been reported to occur immediately before, or at the time of neutrophil engraftment.
Following hematopoietic cell transplantation (HCT), various clinical abnormalities such as noninfectious fever, weight gain due to capillary leakage, hepatic dysfunction, and renal insufficiency have been reported to occur immediately before, or at the time of neutrophil engraftment. [1] [2] [3] [4] [5] [6] These peri-engraftment clinical abnormalities (PECAs) have been described most often in the setting of autologous HCT, 1,2 usually as a part of the engraftment syndrome or capillary leakage syndrome, with widely variable incidences and heterogenous risk factors. While cellular and cytokine interactions associated with neutrophil and lymphocyte recovery are believed to be responsible for the occurrence of PECAs, the distinct pathophysiologic mechanisms have not been clearly defined. 3 PECAs have also been described in the allogeneic HCT setting. [4] [5] [6] However, only a few studies with a limited number of patients have been reported to date, and thus, little is known about the clinical significance of PECAs in the allogeneic HCT setting. To characterize PECAs and to evaluate their clinical significance following allogeneic HCT, we retrospectively analyzed the data of 216 consecutive allogeneic HCT recipients.
Patients and methods

Patients and transplant procedure
We retrospectively reviewed the data of all consecutive adult patients who underwent allogeneic HCT between December 1993 and December 2001 at the Asan Medical Center, University of Ulsan, Seoul, Korea. Data were retrieved from the allogeneic HCT database of Asan Medical Center that includes all the clinical and laboratory data that were monitored and recorded prospectively. These data were verified by reviewing patients' medical records.
Written informed consent for hematopoietic cell collection and transplantation was obtained from patients and donors. All study protocols for specific conditioning regimens and graft-versus-host disease (GVHD) prophylaxis were approved by the Institutional Review Board. Before July 1999, all patients with malignant disorders, including myelodysplastic syndrome (MDS), received a Bu-Cy regimen (busulfan 4 mg/kg/day orally on days À7 to À4 and cyclophosphamide 60 mg/kg/day by intravenous infusion on days À3 to À2) and patients with severe aplastic anemia received a Cy-ATG regimen (cyclophosphamide 50 mg/kg/day by intravenous infusion on days À5 to À2 and antithymocyte globulin 30 mg/kg/day by intravenous infusion on days À4 to À2) for conditioning. After July 1999, a nonmyeloablative conditioning regimen of Bu-Flu-ATG (busulfan 4 mg/kg/day orally on days À7 and À6, fludarabine 30 mg/m 2 /day by intravenous infusion on days À7 toÀ2, and antithymocyte globulin 20 mg/kg/ day by intravenous infusion on days À5 to À2) was given to patients with acute leukemia, who were elderly or had comorbidity, patients with chemotherapy-refractory malignancies, and patients with low-risk MDS or paroxysmal nocturnal hemoglobinuria. 7 Patients who received the BuFlu-ATG regimen received G-CSF-mobilized peripheral blood hematopoietic cells on days 0 and 1. None of the hematopoietic cell grafts was T-cell depleted. HLA matching for donor selection was based on serologic typings for HLA-A, B, and C antigens and a molecular typing for HLA-DRB1 antigen. For unrelated donors, six antigens of HLA-A, B, and DRB1 were considered. GVHD prophylaxis consisted of cyclosporine alone or cyclosporine and a short course of methotrexate. All patients received G-CSF 450 mg intravenously daily starting on day 0 or day 5 of infusion of donor hematopoietic cells until peripheral blood absolute neutrophil count reached over 3000/ ml. Ciprofloxacin and acyclovir were administered for gut decontamination and viral prophylaxis, respectively. On the first neutropenic fever over 38.31C, blood and urine cultures and chest X-ray were obtained and empirical antibiotic therapy with ceftazidime, amikacin, and vancomycin was started. Since February 1998, this regimen has been changed to ceftazidime, piperacilin, and vancomycin to reduce renal toxicity. For nonresponding fever of more than 2 days duration , amphotericin-B was started. These regimens were continued until the absolute neutrophil count reached over 1000/ml and patients became afebrile. In cases of unexplained and persistent pulmonary infiltrates, bronchoscopy with brochoalveolar lavage was performed. All bronchoalveolar lavage samples were evaluated for Penumocystis carinii and cytomegalovirus in addition to routine bacterial and fungal cultures being taken. All patients were monitored prospectively for the occurrence of adverse events, including GVHD, veno-occlusive disease of the liver (VOD), regimen-related toxicities, and infections. Acute and chronic GVHD were classified according to the criteria of Przepiorka et al 8 and Sullivan, 9 respectively. A diagnosis of VOD was made according to the clinical criteria of McDonald et al.
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Definition of clinical parameters
Engraftment was defined as the first day the absolute neutrophil count exceeded 500/ml for two consecutive days. The peri-engraftment period (PEP) was defined as within 4 days prior to, or after engraftment. The following clinical abnormalities were considered to be PECA if each of the abnormalities occurred during the PEP: fever (temperature of 38.31C or over) with no identifiable microbiological, radiological, or clinical infectious etiology; hepatic dysfunction with either total bilirubin X2 mg/dl or transaminase levels Xtwice the upper-normal limit; renal insufficiency with serum creatinine Xtwice the baseline level; weight gain due to capillary leakage X5% of baseline body weight with a reduction of albumin level X10% of baseline albumin level. The criterion for weight gain due to capillary leakage was based on the study by Lee et al, 1 in which they observed that weight gain due to capillary leakage was accompanied by a reduction of albumin level due to leakage of albumin because of increased vascular permeability. The baseline values of creatinine, body weight, and albumin used in this study were those present 4 days prior to engraftment. If values 4 days prior to engraftment were not available, those of 5 days prior to engraftment were used as baseline values.
Statistical methods
Associations in 2 Â n tables were analyzed with w 2 or Fisher's exact test. The cumulative incidences of GVHD were calculated using the Kaplan-Meier method and were compared using a log-rank test. The variables that we analyzed for their impact on the occurrence of PECAs included sex, age (o35 vs X35 years), underlying diagnosis, risk status at HCT (standard vs high risk), conditioning regimen (Bu-Cy vs Cy-ATG vs Bu-Flu-ATG), source of stem cells (bone marrow vs peripheral blood), donor type (matched sibling vs matched unrelated donor or mismatched donor), GVHD prophylaxis regimen (cyclosporine þ methotrexate vs cyclosporine alone), CD34 cell dose (p3.55 vs 43.55 Â 10 6 /kg), and time to engraft (p16 vs 416 days post HCT). The potential predictive factors for occurrence of PECAs identified on univariate analysis at a significance level of Pp0.1 were included as terms in a forward conditional stepwise logistic regression analysis. All statistical tests were two-sided, with Pp0.05 indicating statistical significance.
Results
Patient characteristics
Between December 1993 and December 2001, 222 consecutive adult patients with various malignant and nonmalignant disorders underwent allogeneic HCT at Asan Medical Center. Of these 222 patients, six patients died before engraftment. Data of the remaining 216 patients were analyzed in terms of PECAs. The clinical characteristics of the patients were described in Table 1 Table 2 summarizes the clinical features of PECAs.
Clinical features of PECAs
Noninfectious fever. Fever occurred in 68 patients during the PEP. Of these patients, 10 patients revealed clinical evidence of infection (five with pneumonia, two with bacteremia, two with pneumonia and bacteremia, one with meningitis). Thus, there were 58 cases (27%) of noninfectious fever. Noninfectious fever occurred at a median of 3 days before engraftment.
Peri-engraftment clinical abnormalities
Hepatic dysfunction. During the PEP, 75 patients had abnormal liver function. In 36 of these 75 patients, hepatic dysfunction occurred before the PEP (VOD in 33, GVHD in one, biliary obstruction in one, nondiagnostic in one) and these cases were excluded from the analysis. Hepatic dysfunction occurred during the PEP in the remaining 39 patients (18%) at a median of 1 day before engraftment. Peri-engraftment hepatic dysfunction manifested as elevations of bilirubin and transaminase in 21 patients, an elevation of transaminase in 11 and an elevation of bilirubin in seven patients. The median level of maximally elevated bilirubin was 2.8 (range, 2.1-20.6). The median level of maximally elevated transaminase was 5.4 times the upper-normal limit (range, 2.0-39.4). The clinical diagnoses of these 39 patients included VOD in 10 patients, acute GVHD in four, and nondiagnostic in 25 patients. Cases were regarded as nondiagnostic when they had elevated transaminase without elevated bilirubin or elevated bilirubin (with or without elevated transaminase) that did not meet the criteria for VOD and did not accompany other signs of GVHD, such as a rash or diarrhea.
Weight gain due to capillary leakage. Weight gain occurred in 22 patients (10%) during the PEP at a median of the day of engraftment. The median of maximal weight gain was 7% of baseline body weight (range, 5-14). The median of maximal albumin level reduction was 23% of the baseline level (range, 11-33).
Renal insufficiency. Renal insufficiency occurred in 11 patients (5%) during the PEP at a median of the day of engraftment. The median level of maximally elevated creatinine was 2.7 times the baseline creatinine level (range,
2.3-4).
Inter-relationship between PECAs. Table 3 shows the results of correlation between PECAs. All the PECAs closely correlated with each other.
Predictive clinical factors for the occurrence of PECAs
In multivariate analyses, the following factors were predictive of a significantly higher incidence of PECAs (Table 4) : (1) HCT from an unrelated or mismatched donor, and GVHD prophylaxis with cyclosporine alone for noninfectious fever; (2) HCT from an unrelated or mismatched donor, and rapid engraftment (engraftment within 16 days post HCT) for hepatic dysfunction; and (3) GVHD prophylaxis with cyclosporine alone, and high risk at HCT for weight gain due to capillary leakage. 
GVHD and PECAs
To evaluate correlation between GVHD and PECAs, we compared the cumulative incidence of GVHD between the groups with or without each PECA. As shown in Table 5 , patient groups with each PECA showed a higher incidence of acute or chronic GVHD with varying degrees of statistical significance. This trend was more evident when analyses were limited to more severe forms of acute (grades 3-4) or chronic (extensive) GVHD.
Discussion
In this study, we tried to characterize the clinical features of PECAs and correlate them with various clinical factors to identify their clinical significance. When we analyzed the interrelationship between PECAs, we found that PECAs closely correlated with each other. However, it was not clear whether this clustering of PECAs was due to a common pathophysiologic mechanism or due to different pathophysiologic mechanisms that developed simultaneously during the PEP. Through the correlation analyses between each PECA and other clinical factors, we found some clues to this question. The most frequently identified predictive clinical factors for a higher incidence of each PECA were HCT from an unrelated or mismatched donor, GVHD prophylaxis with cyclosporine alone, and rapid engraftment. Considering that donor type and GVHD prophylaxis regimen are closely associated with GVHD, these observations suggest that the development of PECAs might be related to the graft-versus-host (GVH) reaction. Through the analyses that evaluated the association between PECAs and GVHD, we found clinical evidence supporting this hypothesis. As shown in Table 5 , patient groups with each PECA showed a higher incidence of acute or chronic GVHD with varying degrees of significance. This trend was more evident when analyses were limited to severe forms of acute (grades 3-4) or chronic (extensive) GVHD. Although our data should be interpreted cautiously considering their retrospective nature, it is tempting to speculate that the GVH reaction might be one of the possible pathophysiologic mechanisms for the development of PECAs after allogeneic HCT and, some PECAs might be atypical manifestations of acute GVHD. Of course, not all PECAs are manifestations of the GVH reaction. For example, not all 'noninfectious' febrile episodes would be truly noninfectious because some of the febrile episodes of infectious etiology may not reveal any microbiological, radiological, or clinical evidence of infection. Also in cases reported that six of eight patients who received genotypically nonidentical grafts experienced capillary leak syndrome. Nurnberger et al 5 also reported a higher incidence of capillary leak syndrome among recipients of unrelated HCT compared to recipients of allogeneic-related HCT. In a study with 61 patients who underwent allogeneic HCT, they reported that nine of 21 patients who received unrelated HCT experienced capillary leak syndrome, as did eight of 40 patients who received related HCT. Most of these studies suggesting a correlation between GVHD and PECAs were based on observations in a very limited number of patients and focused on only a proportion of PECAs. To date, therefore, there have not been sufficient data to support the role of a GVH reaction on the occurrence of PECAs. To the best of our knowledge, our study seems to be the first to report the potential role of a GVH reaction on the development of various PECAs after allogeneic HCT by analysis of an adequate number of patients.
Also to be noted is the association of PECAs with a steep neutrophil recovery. This observation points to a role for neutrophils in the pathogenesis of PECAs after allogeneic HCT. Considering that neutrophils can mediate tissue injury, 11 they might have contributed directly to the occurrence of PECAs. However, it cannot be excluded that steep neutrophil recovery is merely an epiphenomenon due to GVH reaction-associated cytokine cascade that activates neutrophil regeneration.
In conclusion, although our data should be interpreted cautiously considering their retrospective nature, some of the PECAs occurring after allogeneic HCT might be atypical manifestations of GVHD and might be associated with severe forms of acute or chronic GVHD. To validate this hypothesis, we anticipate future studies defining the cellular and cytokine profiles of PECAs.
